Каннабиноидергическая регуляция функционального состояния сердца (часть I)

Автор: Крылатов А.В., Серебров В.Ю., Ваизова О.Е., Дьякова Е.Ю.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Статья в выпуске: 3 т.32, 2017 года.

Бесплатный доступ

Установлено, что у наркотизированных животных каннабиноиды вызывают продолжительную гипотензию и брадикардию, которые являются следствием стимуляции СВ1-рецепторов. Эндогенные каннабиноиды не участвуют в регуляции частоты сердечных сокращений и артериального давления у интактных животных. Исследования, выполненные на больных ишемической болезнью сердца, показали, что марихуана может провоцировать приступ стенокардии. Установлено, что каннабиноиды вызывают продолжительную гипотензию и брадикардию, которым могут предшествовать транзиторная тахикардия и гипертензия, связанные с активацией ваниллоидных TRPV1 ре-цепторов. Продолжительная гипотензия - результат прямого действия каннабиноидов на артерии.

Еще

Эндогенные каннабиноиды, сердце

Короткий адрес: https://sciup.org/149125173

IDR: 149125173 | DOI: 10.29001/2073-8552-2017-32-3-7-13

Список литературы Каннабиноидергическая регуляция функционального состояния сердца (часть I)

Mechoulam R., Gaoni Y. Hashish -IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids//Tetrahedron. -1965. -Vol. 21, No. 5. -P. 1223-1229.
Matsuda L.A., Lolait S.J., Brownstein M.J. et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA//Nature. -1990. -Vol. 346, No. 6284. -P. 561-564.
Howlett A.C., Blume L.C., Dalton G.D. CB1 cannabinoid receptors and their associated proteins//Curr. Med. Chem. -2010. -Vol. 17, No. 14. -P. 1382-1393.
Bonz A., Laser M., Küllmer S. et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle//J. Cardiovasc. Pharmacol. -2003. -Vol. 41, No. 4. -P. 657-664.
Wagner J.A., Hu K., Karcher J. et al. CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction//Br. J. Pharmacol. -2003. -Vol. 138, No. 7. -P. 1251-1258.
Wang P.F., Jiang L.S., Bu J. et al. Cannabinoid-2 receptor activation protects against infarct and ischemia/reperfusion heart injury//J. Cardiovasc. Pharmacol. 2012. -Vol. 59, No. 4. -P. 301-307.
Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids//Nature. -1993. -Vol. 365, No. 6441. -P. 61-65.
Dalton G.D., Bass C.E., Van Horn C.G., Howlett A.C. Signal transduction via cannabinoid receptors//CNS Neurol. Disord. Drug Targets. -2009. -Vol. 8, No. 6. -P. 422-431.
Galiegue S., Mary S., Marchand J. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations//Eur. J. Biochem. -1995. -Vol. 232, No. 1. -P. 54-61.
Onaivi E.S., Ishiguro H., Gong J.P. et al. Endocannabinoids and the cardiovascular system in health and disease. In: Endocannabinoids//Pertwee, Roger G. (Ed.), Handb. Exp. Pharmacol. -2015. -No. 231. -P. 393-422.
Shmist Y.A., Goncharov I., Eichler M. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production//Mol. Cell. Biochem. -2006. -Vol. 283, No. 1-2. -P. 75-83.
Weis F., Beiras-Fernandez A., Sodian R. et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated en-docannabinoid system in patients with severe heart failure//J. Mol. Cell. Cardiol. -2010. -Vol. 48, No. 6. -P. 1187-1193.
Sawzdargo M., Nguyen T., Lee D.K. et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ψGPR53 and GPR55: GPR55 is extensively expressed in human brain//Brain Res. Mol. Brain Res. -1999. -Vol. 64, No. 2. -P. 193-198.
Ryberg E., Larsson N., Sjögren S. et al. The orphan receptor GPR55 is a novel cannabinoid receptor//Br. J. Pharmacol. -2007. -Vol. 152, No. 7. -P. 1092-1101.
Devane W.A., Hanus L., Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor//Science. -1992. -Vol. 258, No. 5090. -P. 1946-1949.
Mechoulam R., Ben-Shabat S., Hanuš L. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors//Biochem. Pharmacol. -1995. -Vol. 50, No. 1. -P. 83-90.
Hanus L., Abu-Lafi S., Fride E. et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor//Proc. Natl. Acad. Sci. USA. -2001. -Vol. 98, No. 7. -P. 3662-3665.
Leggett J.D., Aspley S., Beckett S.R. et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors//Br. J. Pharmacol. -2004. -Vol. 141, No. 2. -P. 253-262.
Milman G., Maor Y., Abu-Lafi S. et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties//Proc. Natl. Acad. Sci. USA. -2006. -Vol. 103, No. 7. -P. 2428-2433.
Gomes I., Grushko J.S., Golebiewska U. et al. Novel endogenous peptide agonists of cannabinoid receptors//FASEB J. -2009. -Vol. 23, No. 9. -P. 3020-3029.
Pertwee R.G. Endocannabinoids and their pharmacological actions. In: Endocannabinoids//Pertwee Roger G. (Ed.), Handb. Exp. Pharmacol. -2015. -No. 231. -P. 1-37.
Holman E.A., Guijarro A., Lim J., Piomelli D. Effects of acute stress on cardiac endocannabinoids, lipogenesis, and inflammation in rats//Psychosom. Med. -2014. -Vol. 76, No. 1. -P. 20-28.
Tuma R.F., Steffens S. Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury//Curr. Pharm. Biotechnol. -2012. -Vol. 13, No. 1. -P. 46-58.
Wagner J.A., Abesser M., Harvey-White J., Ertl G. 2-Arachidonyl-glycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts//J. Cardiovasc. Pharmacol. -2006. -Vol. 47, No. 5. -P. 650-655.
Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension//FASEB J. -1998. Vol. 12, No. 11. P. 1035-1044.
Cabral G.A., Ferreira G.A., Jamerson M.J. Endocannabinoids and the immune system in health and disease. In: Endocannabinoids//Pertwee Roger G. (Ed.) Handb. Exp. Pharmacol. -2015. -No. 231. -P. 185-211.
Cascio M.G., Marini P. Biosynthesis and fate of endocannabinoids. In: Endocannabinoids//Pertwee Roger G. (Ed.), Handb. Exp. Pharmacol. -2015. -No. 231. -P. 39-58.
Hollister L.E., Richards R.K., Gillespie H.K. Comparison of tetrahydrocannabinol and synhexl in man//Clin. Pharmacol. Ther. -1968. -Vol. 9, No. 6. -P. 783-791.
Domino E.F. Neropsychologic studies of marihuana. Some synthetic and natural THC derivates in animals and man//Ann. N.Y. Acad. Sci. -1971. -No. 191. -P. 166-191.
Malit L.A., Johnstone R.E., Bourke D.I. et al. Intravenous Δ9-tetrahydrocannabinol: Effects on ventilatory control and cardiovascular dynamics//Anesthesiology. -1975. -Vol. 42, No. 6. -P. 666-673.
Dewey W.L., Jenkins J., O'Rourke T., Harris L.S. The effect of chronic administration of trans-Δ9-tetrahydrocannabinol on behavior and the cardiovascular system of dogs//Arch. Int. Pharmacodyn. Ther. -1972. -Vol. 198, No. 1. -P. 118-131.
Cavero I., Ertel R., Buckley J.P., Jandhyala B.S. Effects of (-)-Δ9-trans-tetrahydrocannabinol on regional blood flow in anesthetized dogs//Eur. J. Pharmacol. -1972. -Vol. 20, No. 3. -P. 373-376.
Perez-Reyes M., Timmons M.C., Lipton M.A. et al. Intravenous injection in man of Δ9-tetrahydrocannabinol and 11-OH-Δ9-tetrahydrocannabinol//Science -1972. -Vol. 177, No. 49. -P. 633-635.
Perez-Riyes M., Timmons M.C., Davis K.H., Wall E.M. A comparison of the pharmacological activity in man of intravenously administered Δ9-tetrahydrocannabinol, cannabinol, and cannabidiol//Experientia. -1973. -Vol. 29, No. 11. -P. 1368-1369.
Cavero I., Buckley J.P., Jandhyala B.S. Hemodynamic and myocardial effects of (-)-Δ9-trans-tetrahydrocannabinol in anesthetized dogs//Eur. J. Pharmacol. -1973. -Vol. 24, No. 2. -P. 243-251.
Gorelick D.A., Goodwin R.S., Schwilke E. et al. Tolerance to effects of high-dose oral Δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers//J. Anal. Toxicol. -2013. -Vol. 37, No. 1. -P. 11-16.
Kaymakcalan S., Sivil S. Lack of tolerance to the bradycardic effect of D9-trans-tetrahydrocannabinol in rats//Pharmacology. -1974. -Vol. 12, No. 4-5. -P. 290-295.
Adams M.D., Chait L.D., Earnhardt J.T. Tolerance to the cardiovascular effects of Δ9-tetrahydrocannabinol in the rat//Br. J. Pharmacol. -1976. -Vol. 56, No. 1. -Р. 43-48.
Hine B., Torrelio M., Gershon S. Analgesic, heart rate, and temperature effects of D8-THC during acute and chronic administration to conscious rats//Pharmacology -1977. -Vol. 15, No. 1. -P. 65-72.
Hine B. Morphine and D9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat//Psychopharmacology. -1985. -Vol. 87, No. 1. -P. 34-38.
Jandhyala B.S., Hamed A.T. Pulmonary and systemic hemodynamic effects of delta9-tetrahydrocannabinol in conscious and morphine-chloralose-anesthetized dogs: anesthetic influence on drug action//Eur. J. Pharmacol. -1978. -Vol. 53, No. 1. -P. 63-68.
Stark P., Dews P.B. Cannabinoids. II. Cardiovascular effects//J. Pharmacol. Exp. Ther. -1980. -Vol. 214, No. 1. -P. 131-138.
Kawasaki H., Watanabe S., Ueki S. Effects of chronic administration of delta 9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in freely moving rats//Eur. J. Pharmacol. -1980. -Vol. 65, No. 1. -P. 63-69.
Friedman E., Gershon S., Hine B., Torrelio M. Cardiovascular effects of D9-tetrahydrocannabinol in conscious and anesthetized dogs//Br. J. Pharmacol. -1977. -Vol. 59, No. 4. -P. 561-563.
Маслов Л.Н., Хедрик Дж.П., Мешоулам Р. и др. Роль транс-активации рецепторов в кардиопротекторных эффектах прекондиционирования и посткондиционирования//Рос. физиол. журн. -2012. -Т. 98, № 3. -С. 305-317.
Cavero I., Lokhandwala M.F., Buckley J.P., Jandhyala B.S. The effect of (-)-Δ9-trans-tetrahydrocannibinol on myocardial con-tractility and venous return in anesthetized dogs//Eur. J. Pharmacol. -1974. -Vol. 29, No. 1. -P. 74-82.
Aronow W.S., Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris//N. Engl. J. Med. -1974. -Vol. 291, No. 2. -P. 65-67.
Vivan J.A., Kishioka S., Butelman E.R. et al. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A//J. Pharmacol. Exp. Ther. -1998. -Vol. 286, No. 2. -P. 697-703.
Vidrio H., Sanchez-Salvatori M.A., Medina M. Cardiovascular effects of (-)-11-OH-D8-tetrahydrocannabinol-dimethylheptyl in rats.//J. Cardiovasc. Pharmacol. -1996. -Vol. 28, No. 2. P. 332-336.
Pertwee R.G. Pharmacology of cannabinoid receptor ligands//Curr. Med. Chem. -1999. -Vol. 6, No. 8. -P. 635-664.
Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. Can-nabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors//J. Pharmacol. Exp. Ther. -1997. -Vol. 81, No. 3. -P. 1030-1037.
Krylatov A.V., Maslov L.N., Ermakov S.Yu. et al. Significance of cardiac cannabinoid receptors in regulation of cardiac rhythm, myocardial contractility, and electrophysiologic process in heart//Biol. Bull. -2007. -Vol. 34, No. 1. -P. 28-35.
Malinowska B., Kwolek G., Gothert M. Anandamide and methanandamide induce both vanilloid VR1-and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats//Naunyn-Schmiedeberg's Arch. Pharma-col. 2001. -Vol. 364, No. 6. -P. 562-569.
Gardiner S.M., March J.E., Kemp P.A., Bennett T. Complex regional haemodynamic effects of anandamide in conscious rats//Br. J. Pharmacol. -2002. -Vol. 135, No. 8. -P. 1889-1896.
Pacher P., Batkai S., Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice//J. Physiol. -2004. -Vol. 558, Pt. 2. -P. 647-657.
Zuurman L., Passier P.C., de Kam M. et al. Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers//J. Psychopharmacol. -2009. -Vol. 23, No. 6. -P. 633-644.
Stanley C.P., Hind W.H., Tufarelli C., O'Sullivan S.E. Cannabidiol causes endothelium-dependent vasorelaxation of human mes-enteric arteries via CB1 activation//Cardiovasc. Res. -2015. -Vol. 107, No. 4. -P. 568-578.
AlSuleimani Y.M., Hiley C.R. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca2+ release in rat mesenteric artery endothelial cells//Br. J. Pharmacol. -2015. -Vol. 172, No. 12. -P. 3043-3057.
O'Sullivan S.E. Endocannabinoids and the cardiovascular system in health and disease. In: Endocannabinoids//Pertwee, Roger G. (Ed.), Handb. Exp. Pharmacol. -2015. -Vol. 231. -P. 393-422.

Еще

Статья научная